Antibody-drug conjugates offer a more targeted approach to treatment, with fewer side effects than traditional systemic therapies. Make sure your team understands how these agents fit into the current treatment landscape by tuning in to Part 3 of our Breast Cancer Hot Topics series! Leading breast cancer experts will review: underlying mechanism of action and targets for antibody-drug conjugates in breast cancer available evidence for approved and emerging antibody-drug conjugates in breast cancer real-world patient cases where you will have the chance to test your skills. This activity is delivered in partnership with After Breast Cancer Diagnosis (ABCD).
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/antibody-drug-conjugates-breast-cancer
- Start Date: 2024-08-23 05:00:00
- End Date: 2024-08-23 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 11250.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 11250.0 - Is Kind Support: False Source: Gilead Sciences, Inc. - Amount: 8291.67 - Is Kind Support: False Source: Merck (Any division) - Amount: 8333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest